Wird geladen...

A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial

Hematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have increased graft-vs.-host disease (GVHD) and non-relapse mortality (NRM). Bortezomib added to reduced-intensity conditioning can offer benefit in T-replete HLA-mismatched HSCT, and may also benefit myelo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biol Blood Marrow Transplant
Hauptverfasser: Koreth, John, Kim, Haesook T., Lange, Paulina B., Bindra, Bhavjot, Reynolds, Carol G., Chammas, Marie J., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Glotzbecker, Brett, Nikiforow, Sarah, Ritz, Jerome, Blazar, Bruce R., Soiffer, Robert J., Antin, Joseph H., Alyea, Edwin P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604028/
https://ncbi.nlm.nih.gov/pubmed/26055298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.05.027
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!